1. Generics Bulletin

Long-Term Biosimilar Sustainability Is At A Tipping Point, Report Says

New Policy Levers Are Needed For A Balanced And Sustainable Biosimilar Market

 
• By Urtė Fultinavičiūtė

The current cost-saving benefits of biosimilars may soon be overturned by an unsustainable system that favors originator drugs, lower profits, and increased discounts, according to a new report.

Stack of coins with red and green graph arrows pointing up and down
Biosimilars may save $180bn between 2023 and 2027 • Source: Shutterstock

While biosimilar medicines have offered a great deal of savings for US healthcare, the current system may negatively affect the long-term sustainability of the sector, potentially leading to a decrease in biosimilar developers and monopolization of the market, suggests a new IQVIA report.

According to the report titled “Long-term Market Sustainability for Infused Biosimilars in the US”, biosimilars have been associated with $56bn in savings between 2013 and 2022 and hold the potential for over $180bn in savings between 2023 and 2027

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products